Research and Markets (http://www.researchandmarkets.com/reports/c69309) has announced the addition of new Decision Resources report Change Is Percolating Through Japan's Pharmaceutical Markets to their offering.
Japan's pharmaceutical markets are increasingly more competitive, and a steady restructuring of the Japanese pharmaceutical industry is under way. The government continues to tighten its control over drug expenditures, and foreign and multinational pharmaceutical companies are strengthening their foothold in Japan by launching a wide variety of new drugs. To successfully navigate the changing waters of the world's second-largest pharmaceutical market, companies must understand today's evolving business environment and institute a plan of action to realize their mid- to long-term visions.
Get the Answers You Need to Shape Your Strategy
The Japanese government intended to implement annual price revisions in fiscal year 2007, but the measure has been temporarily shelved, because many thorny issues regarding Japanese practices of dispensing drugs need to be resolved before annual price revisions can be instituted. Nevertheless, why should the pharmaceutical industry in Japan anticipate that the government may implement annual price revisions in a high-handed manner in fiscal year 2009?
- The advent of "triangular mergers," whereby foreign companies are allowed to use their stock to acquire or merge with Japanese companies, arrived in May 2007. Why is this new M&A tool particularly likely to accelerate the restructuring of Japan's marketplace? Why might Takeda represent an especially attractive takeover target?
- The Japanese market continues to be subject to less aggressive generic erosion than the pharmaceutical markets in the United States and in some European countries. But in May 2007, the government called for an increase in the market share of generics from 16.8% (by volume) in 2004 to at least 30% in 2012. In spite of the government's goal, why may some branded drugs remain impervious to generics competition?
- Japanese pharma's growing interest in biologics is reflected not only in several recent deals for biologics but also in an expanding pipeline of late-stage recombinant proteins and monoclonal antibodies (MAbs). Which Japanese companies historically having little interest in biologics now have one or more biologics in late-stage development? Which companies have entered into deals in 2007 to acquire MAbs and MAb technology?
- The Japanese government aggressively cut prices for long-listed drugs in 2006, after indicating that a similar cut in 2004 was meant to be a one-time event. Which type of company has the additional price cut proven particularly hurtful to?
Scope
- The Japanese pharma landscape: market size and demographics; growth rate of health care expenditures; overall health care expenditures relative to gross domestic product; total market value of Japan's largest domestic pharmaceutical companies; best-selling drugs in Japan.
- The government's role in containing drug expenditure costs: cost-containment measures by the Ministry of Health, Labor, and Welfare; Japan's National Health Insurance system; biennial drug price revisions; increased emphasis on promoting generic drugs; the DPC "fl at sum" reimbursement system; proposals to revise drug prices annually; price cuts for long-listed drugs.
- Japanese biologics: dominant players in the Japanese biologics markets; late-stage biologics in Japanese company pipelines.
- Generics: the growing acceptance of generics within the Japanese marketplace; the government's increased emphasis on generics; reimbursement system for hospitals; new entrants in the Japanese generics market; overall outlook for the Japanese generics market.
- The growing impact of foreign companies: the strengthening foothold of multinational companies; increased competition for domestic pharmaceutical companies; efforts to accelerate the launch of global drugs in Japan.
- Recent mergers and acquisitions: Chugai and Roche Nippon; Daiichi and Sankyo; Dainippon and Sumitomo; Tanabe and Mitsubishi; Yamanouchi and Fujisawa; revisions in corporate law to provide for "triangular" mergers.
- Navigating Japan pharma's stormy waters: outlook for growth in the Japanese pharmaceutical market; the probability that M&A activity will continue for Japanese companies; ongoing attempts to improve the reliability of generics; the ongoing fight for market share; the need for companies to devise a plan of action.
|
